173 related articles for article (PubMed ID: 24667717)
1. Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide).
Morris RT; Joyrich RN; Naumann RW; Shah NP; Maurer AH; Strauss HW; Uszler JM; Symanowski JT; Ellis PR; Harb WA
Ann Oncol; 2014 Apr; 25(4):852-858. PubMed ID: 24667717
[TBL] [Abstract][Full Text] [Related]
2. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
Naumann RW; Coleman RL; Burger RA; Sausville EA; Kutarska E; Ghamande SA; Gabrail NY; Depasquale SE; Nowara E; Gilbert L; Gersh RH; Teneriello MG; Harb WA; Konstantinopoulos PA; Penson RT; Symanowski JT; Lovejoy CD; Leamon CP; Morgenstern DE; Messmann RA
J Clin Oncol; 2013 Dec; 31(35):4400-6. PubMed ID: 24127448
[TBL] [Abstract][Full Text] [Related]
3. The folate receptor as a rational therapeutic target for personalized cancer treatment.
Assaraf YG; Leamon CP; Reddy JA
Drug Resist Updat; 2014; 17(4-6):89-95. PubMed ID: 25457975
[TBL] [Abstract][Full Text] [Related]
4. Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging.
Maurer AH; Elsinga P; Fanti S; Nguyen B; Oyen WJ; Weber WA
J Nucl Med; 2014 May; 55(5):701-4. PubMed ID: 24732155
[TBL] [Abstract][Full Text] [Related]
5. Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial.
Herzog TJ; Kutarska E; Bidzińsk M; Symanowski J; Nguyen B; Rangwala RA; Naumann RW
Int J Gynecol Cancer; 2016 Nov; 26(9):1580-1585. PubMed ID: 27654255
[TBL] [Abstract][Full Text] [Related]
6. Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer.
Ambrosio AJ; Suzin D; Palmer EL; Penson RT
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):443-50. PubMed ID: 24742319
[TBL] [Abstract][Full Text] [Related]
7. Vintafolide: a novel targeted agent for epithelial ovarian cancer.
Graybill WS; Coleman RL
Future Oncol; 2014 Mar; 10(4):541-8. PubMed ID: 24754586
[TBL] [Abstract][Full Text] [Related]
8. Clinical translation of folate receptor-targeted therapeutics.
Teng L; Xie J; Teng L; Lee RJ
Expert Opin Drug Deliv; 2012 Aug; 9(8):901-8. PubMed ID: 22663189
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical trial of 99mTc-etarfolatide, an imaging agent for folate receptor in healthy Japanese adults.
Yamada Y; Nakatani H; Yanaihara H; Omote M
Ann Nucl Med; 2015 Nov; 29(9):792-8. PubMed ID: 26238440
[TBL] [Abstract][Full Text] [Related]
10. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.
Ledermann JA; Canevari S; Thigpen T
Ann Oncol; 2015 Oct; 26(10):2034-43. PubMed ID: 26063635
[TBL] [Abstract][Full Text] [Related]
11. Expression of functional folate receptors by human parathyroid cells.
Weber CJ; Müller S; Safley SA; Gordon KB; Amancha P; Villinger F; Camp VM; Lipowska M; Sharma J; Müller C; Schibli R; Low PS; Leamon CP; Halkar RK
Surgery; 2013 Dec; 154(6):1385-93; discussion 1393. PubMed ID: 24206618
[TBL] [Abstract][Full Text] [Related]
12. Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung.
Edelman MJ; Harb WA; Pal SE; Boccia RV; Kraut MJ; Bonomi P; Conley BA; Rogers JS; Messmann RA; Garon EB
J Thorac Oncol; 2012 Oct; 7(10):1618-21. PubMed ID: 22982661
[TBL] [Abstract][Full Text] [Related]
13. Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide.
Serpe L; Gallicchio M; Canaparo R; Dosio F
Pharmgenomics Pers Med; 2014; 7():31-42. PubMed ID: 24516337
[TBL] [Abstract][Full Text] [Related]
14. High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide.
Guertin AD; O'Neil J; Stoeck A; Reddy JA; Cristescu R; Haines BB; Hinton MC; Dorton R; Bloomfield A; Nelson M; Vetzel M; Lejnine S; Nebozhyn M; Zhang T; Loboda A; Picard KL; Schmidt EV; Dussault I; Leamon CP
Mol Cancer Ther; 2016 Aug; 15(8):1998-2008. PubMed ID: 27256377
[TBL] [Abstract][Full Text] [Related]
15. Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis.
Lake AD; Hardwick RN; Leamon CP; Low PS; Cherrington NJ
Toxicol Appl Pharmacol; 2019 Apr; 368():49-54. PubMed ID: 30794826
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Preclinical Evaluation of Folate-NOTA-Al(18)F for PET Imaging of Folate-Receptor-Positive Tumors.
Chen Q; Meng X; McQuade P; Rubins D; Lin SA; Zeng Z; Haley H; Miller P; González Trotter D; Low PS
Mol Pharm; 2016 May; 13(5):1520-7. PubMed ID: 27054811
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of isostructural Tc-99m- and Re-188-folate-Gly-Gly-Cys-Glu for folate receptor-positive tumor targeting.
Kim WH; Kim CG; Kim MH; Kim DW; Park CR; Park JY; Lee YS; Youn H; Kang KW; Jeong JM; Chung JK
Ann Nucl Med; 2016 Jun; 30(5):369-79. PubMed ID: 26993818
[TBL] [Abstract][Full Text] [Related]
18. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
